Physician profile
Alexander Eswar
NPI 1679714562
$6,038.06
in general payments reported to CMS, 2019-2025
30 companies · $4,598 in 2025
The $4,598 reported for 2025 was more than what 97% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $25.07 · 2021: $93.13 · 2022: $726 · 2023: $105 · 2024: $323 · 2025: $4,598.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,000 · Food and Beverage: $1,026.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,000.00 |
| Food and Beverage | $1,026.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,178.98 | 2025 | |
| Caldera Medical, INC | $643.75 | 2022 | |
| Astellas Pharma US INC | $201.14 | 2023-2025 | Veozah |
| Hologic Sales and Service, LLC | $140.49 | 2021-2024 | Aptima |
| Sumitomo Pharma America, INC. | $89.50 | 2024-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $82.40 | 2024-2025 | |
| Abbvie INC. | $71.31 | 2019-2022 | |
| Millicent US INC | $51.25 | 2019-2025 | Intrarosa, Femlyv, Femring |
| Organon LLC | $50.14 | 2023-2025 | Nexplanon, Nuvaring |
| Coopersurgical, INC. | $46.86 | 2024-2025 | Paragard T 380a |
| Exact Sciences Corporation | $43.93 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $40.22 | 2024-2025 | |
| Janssen Pharmaceuticals, INC | $37.93 | 2019 | |
| Biogen, INC. | $36.67 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $30.94 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $30.45 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $27.59 | 2024 | Gardasil 9, Gardasil |
| Janssen Biotech, INC. | $26.26 | 2022 | |
| Exeltis, USA INC. | $24.41 | 2025 | Slynd |
| Abbott Laboratories | $24.11 | 2022 | |
| Dexcom, INC. | $23.17 | 2025 | Dexcom G6 Transmitter |
| Shield Therapeutics INC | $18.76 | 2025 | |
| Amgen INC. | $18.49 | 2024 | Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $15.77 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.30 | 2019 | |
| Gilead Sciences, INC. | $14.80 | 2023 | |
| Lupin INC. | $14.66 | 2019 | |
| Alexion Pharmaceuticals, INC. | $13.80 | 2019 | |
| Celgene Corporation | $13.74 | 2019 | |
| Sobi, INC | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Eswar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.